Bridge City Capital LLC grew its holdings in shares of Bruker Corporation (NASDAQ:BRKR) by 8.7% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 73,741 shares of the medical research company’s stock after purchasing an additional 5,908 shares during the period. Bruker Corporation comprises 1.6% of Bridge City Capital LLC’s holdings, making the stock its 13th largest holding. Bridge City Capital LLC’s holdings in Bruker Corporation were worth $2,194,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Vanguard Group Inc. grew its position in shares of Bruker Corporation by 2.9% during the 1st quarter. Vanguard Group Inc. now owns 9,832,452 shares of the medical research company’s stock worth $229,391,000 after purchasing an additional 277,111 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in shares of Bruker Corporation by 4.8% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 524,525 shares of the medical research company’s stock worth $12,238,000 after acquiring an additional 24,115 shares during the period. AJO LP bought a new stake in shares of Bruker Corporation during the 2nd quarter worth approximately $46,075,000. Koch Industries Inc. lifted its holdings in shares of Bruker Corporation by 2,573.5% during the 2nd quarter. Koch Industries Inc. now owns 334,774 shares of the medical research company’s stock worth $324,000 after acquiring an additional 322,252 shares during the period. Finally, Victory Capital Management Inc. lifted its holdings in shares of Bruker Corporation by 6.8% during the 2nd quarter. Victory Capital Management Inc. now owns 1,930,209 shares of the medical research company’s stock worth $55,667,000 after acquiring an additional 123,322 shares during the period. Hedge funds and other institutional investors own 65.74% of the company’s stock.

Bruker Corporation (NASDAQ:BRKR) last announced its quarterly earnings data on Thursday, August 3rd. The medical research company reported $0.23 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.20 by $0.03. The firm had revenue of $414.90 million during the quarter, compared to analyst estimates of $384.75 million. Bruker Corporation had a net margin of 9.65% and a return on equity of 26.66%. The business’s quarterly revenue was up 11.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.20 EPS.

BRKR has been the subject of a number of recent analyst reports. Cowen and Company reaffirmed a “hold” rating and set a $29.00 price target on shares of Bruker Corporation in a report on Friday, July 14th. Zacks Investment Research raised shares of Bruker Corporation from a “hold” rating to a “buy” rating and set a $33.00 price target for the company in a report on Thursday, July 6th. Barclays PLC reaffirmed an “equal weight” rating and set a $30.00 price target (up previously from $26.00) on shares of Bruker Corporation in a report on Monday, July 17th. Wells Fargo & Company downgraded shares of Bruker Corporation from a “market perform” rating to an “underperform” rating in a report on Wednesday, July 12th. Finally, BidaskClub downgraded shares of Bruker Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $26.70.

In other Bruker Corporation news, CEO Frank H. Laukien acquired 2,335 shares of the stock in a transaction dated Thursday, August 10th. The stock was purchased at an average cost of $27.39 per share, for a total transaction of $63,955.65. Following the acquisition, the chief executive officer now owns 37,791,386 shares in the company, valued at approximately $1,035,106,062.54. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Mark Munch sold 21,061 shares of the business’s stock in a transaction that occurred on Wednesday, September 13th. The stock was sold at an average price of $29.97, for a total transaction of $631,198.17. Following the completion of the sale, the vice president now owns 60,524 shares of the company’s stock, valued at $1,813,904.28. The disclosure for this sale can be found here. Insiders own 35.20% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://theolympiareport.com/2017/11/02/bridge-city-capital-llc-has-2-19-million-holdings-in-bruker-corporation-brkr.html.

Bruker Corporation Company Profile

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Institutional Ownership by Quarter for Bruker Corporation (NASDAQ:BRKR)

Receive News & Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.